Chiara Maria Soldavini

Dr. Chiara Maria Soldavini

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
GPGabriele Piuri
Gabriele Piuri
KBKatia Basello
Katia Basello
GRGabriele Rossi
Gabriele Rossi
CSChiara Maria Soldavini
Chiara Maria Soldavini
SDSilvia Duiella
Silvia Duiella
FMFerrazzi Enrico Maria
Ferrazzi Enrico Maria
Background: In gestational diabetes mellitus (GDM), pancreatic β-cell breakdown can result from a proinflammatory imbalance created by a sustained level of cytokines. In this study, we investigated the role of specific cytokines, such as B-cell activating factor (BAFF), tumor necrosis factor α (TNF-α), and platelet-activating factor (PAF), together with methylglyoxal (MGO) and glycated albumin (GA) in pregnant women affected by GDM. Methods: We enrolled 30 women whose inflammation and metabolic markers were measured at recruitment and after 12 weeks of strict dietetic therapy. We compared these data to the data obtained from 53 randomly selected healthy nonpregnant subjects without diabetes, hyperglycemia, or any condition that can affect glycemic metabolism. Results: In pregnant women affected by GDM, PAF levels increased from 26.3 (17.4–47.5) ng/mL to 40.1 (30.5–80.5) ng/mL (p < 0.001). Their TNF-α levels increased from 3.0 (2.8–3.5) pg/mL to 3.4 (3.1–5.8) pg/mL (p < 0.001). The levels of methylglyoxal were significantly higher in the women with GDM (p < 0.001), both at diagnosis and after 12 weeks (0.64 (0.46–0.90) μg/mL; 0.71 (0.47–0.93) μg/mL, respectively) compared to general population (0.25 (0.19–0.28) μg/mL). Levels of glycated albumin were significantly higher in women with GDM (p < 0.001) only after 12 weeks from diagnosis (1.51 (0.88–2.03) nmol/mL) compared to general population (0.95 (0.63–1.4) nmol/mL). Conclusion: These findings support the involvement of new inflammatory and metabolic biomarkers in the mechanisms related to GDM complications and prompt deeper exploration into the vicious cycle connecting inflammation, oxidative stress, and metabolic results.

8 December 2021 in Pregnancy Hypertension
Verified
Journal Article
Closed access
CSChiara Maria Soldavini
Chiara Maria Soldavini
DMDaniela Di Martino
Daniela Di Martino
ESElisa Sabattini
Elisa Sabattini
SOSara Ornaghi
Sara Ornaghi
VSVittoria Sterpi
Vittoria Sterpi
FMFerrazzi Enrico Maria
Ferrazzi Enrico Maria

2 January 2020 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
FDFrancesco D'Ambrosi
Francesco D'Ambrosi
GRGabriele Rossi
Gabriele Rossi
CSChiara Maria Soldavini
Chiara Maria Soldavini
MMMatteo Di Maso
Matteo Di Maso
ICIlma F. Carbone
Ilma F. Carbone
FMFerrazzi Enrico Maria
Ferrazzi Enrico Maria

16 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
CSChiara Maria Soldavini
Chiara Maria Soldavini
GPGabriele Piuri
Gabriele Piuri
GRGabriele Rossi
Gabriele Rossi
PCPaola Corsetto
Paola Corsetto
LBLinda Benzoni
Linda Benzoni
FMFerrazzi Enrico Maria
Ferrazzi Enrico Maria
Gestational diabetes mellitus (GD) is characterized by glycemic and lipid metabolism alterations in an environment of low-grade inflammation. Our trial aimed to assess the effect of nutraceutical supplements (omega-3 fatty acids, anthocyanins, and alpha-cyclodextrins) in GD patients and evaluate the role of anthropometric, metabolic, and inflammatory parameters as biomarkers to identify subjects who require pharmacological hypoglycemic treatment during gestation. Pregnant women with GD at 24–28 weeks of gestation were enrolled in a double-blind trial and randomized to receive either nutraceutical supplements or a placebo for 12 weeks. No statistically significant differences were observed between the two groups in blood and urine measurements of metabolic, inflammatory, and antioxidant parameters. In the whole cohort, pre-pregnancy BMI and anthropometric measurements were significantly different in patients who required pharmacological intervention. These patients showed higher triglycerides, CRP, and insulin levels and gave birth to newborns with significantly higher weights. Subjects with a greater AA/EPA ratio had higher PAF levels and gave birth four days earlier. In conclusion, one-to-one nutritional coaching and poor compliance with nutraceutical supplementation might have outweighed the impact of this intervention. However, triglyceride concentration and the AA/EPA ratio seems to be a biomarker for higher inflammatory levels and GD candidates for pharmacological treatment. An adequate assumption of omega-3 in women with GD, either by a controlled diet or by nutraceutical supplementation, reduces the need for pharmacological therapy.

7 January 2021 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
FDF. D’ambrosi
F. D’ambrosi
GRG. Rossi
G. Rossi
CSChiara Maria Soldavini
Chiara Maria Soldavini
ICI. F. Carbone
I. F. Carbone
GCG. E. Cetera
G. E. Cetera
EFE. Ferrazzi
E. Ferrazzi

11 December 2020 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
PDF file
FDFrancesco D'Ambrosi
Francesco D'Ambrosi
GRGabriele Rossi
Gabriele Rossi
CSChiara Maria Soldavini
Chiara Maria Soldavini
VMValeria Maggi
Valeria Maggi
GCGiulia Emily Cetera
Giulia Emily Cetera
EFEnrico Ferrazzi
Enrico Ferrazzi
Objective In this study we describe the management of women with gestational diabetes (GD) and an ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of the study is to evaluate whether coronavirus disease 2019 (COVID-19) can further complicate pregnancies, and if the protocol we usually use for GD pregnancies is also applicable to patients who have contracted a SARS-CoV-2 infection. Methods This is a retrospective study analyzing all pregnant women with GD and concomitant COVID-19 admitted to our institution for antenatal care between March 1 and April 30, 2020. Results Among pregnant women with GD and a concomitant SARS-CoV-2 infection, the mean age was 32.9 (SD 5.6) years. Two patients (33%) were of white racial origin and four (67%) were of non-white racial origin. All patients were diagnosed with COVID-19 during the third trimester of pregnancy. Two women were asymptomatic and four were symptomatic. Only two (33.3%) women received treatment with insulin. None of the patients required intensive care or mechanical ventilation. No complications were found among the neonates. Conclusion COVID-19 was not found to worsen the prognosis of patients with GD or of their offspring. Glycemic monitoring, diet therapy, and insulin, when needed, are sufficient for good metabolic control and favorable maternal and fetal outcomes.